Bando H, Takagi T, Yamashita F, Takakura Y, Hashida M
Department of Drug Delivery Research, Faculty of Pharmaceutical Sciences, Kyoto University, Japan.
Pharm Res. 1996 Mar;13(3):427-32. doi: 10.1023/a:1016000827719.
A theoretical design of percutaneous penetration enhancement in which prodrug derivation and enhancer application are combined is proposed based on the skin diffusion model and it is experimentally verified.
Employing acyclovir as a model drug, the hypothesis was tested by synthesis of its prodrugs and evaluation of their in vitro permeation in the rat skin, with or without a penetration enhancer, 1-geranylazacycloheptan-2-one(GACH).
Among five acyclovir prodrugs, those with higher lipophilicities (propionate, butyrate, valerate, and hexanoate prodrugs) showed greater skin penetration than those of hydrophilic prodrugs (acetate), when administered in combination with GACH. Furthermore, the observed enhancement ratios were in good agreement with those predicted by theoretical consideration.
Thus, skin permeation of prodrugs applied with an enhancer can be predicted and optimized by model analysis.
基于皮肤扩散模型,提出一种将前药衍生化与渗透促进剂应用相结合的经皮渗透增强理论设计,并进行实验验证。
以阿昔洛韦为模型药物,通过合成其前药并评估其在大鼠皮肤中有或无渗透促进剂1-香叶基氮杂环庚烷-2-酮(GACH)时的体外渗透情况来验证该假设。
在五种阿昔洛韦前药中,与GACH联合给药时,亲脂性较高的前药(丙酸酯、丁酸酯、戊酸酯和己酸酯前药)比亲水性前药(乙酸酯)表现出更大的皮肤渗透性。此外,观察到的增强率与理论预测值高度一致。
因此,通过模型分析可以预测和优化与渗透促进剂一起应用的前药的皮肤渗透性。